CPACS Trial Opens for RC220 Patient Enrolment in Korea

Key points

• First Korean site, Ewha Womans University Seoul Hospital, opened for patient enrollment
• Second and third sites scheduled to open on September 4 and 8, respectively
• Trial aims to assess RC220's cardioprotection and anticancer effects in combination with doxorubicin
• Additional sites expected to accelerate trial progress

Full summary

Racura Oncology Ltd has announced the activation of the first Korean site for its Cardioprotection and Anticancer Synergy (CPACS) Phase 1 trial of RC220, a proprietary formulation of (E,E)-bisantrene, in combination with doxorubicin in patients with advanced solid tumors. The first site, Ewha Womans University Seoul Hospital, has begun pre-screening patients, with treatment of the first patient expected soon. Two additional Korean sites, Severance Hospital and Samsung Medical Center, are scheduled to open on September 4 and 8, respectively. The trial aims to assess the cardioprotective and anticancer effects of RC220, with the opening of these sites expected to accelerate trial progress. The CPACS trial protocol was modified to include a doxorubicin monotherapy cycle to improve patient safety and avoid premature termination of the trial due to side effects from doxorubicin.